ENTRY       D09960                      Drug
NAME        Ruxolitinib phosphate (JAN/USAN);
            Jakafi (TN);
            Jakavi (TN);
            Opzelura (TN)
PRODUCT     JAKAFI (Incyte Corporation)
            OPZELURA (Incyte Corporation)
FORMULA     C17H18N6. H3PO4
EXACT_MASS  404.1362
MOL_WEIGHT  404.3602
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG02020  JAK inhibitor
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 3999 4291
            ATC code: D11AH09 L01EJ01
            Chemical structure group: DG00719
            Product (DG00719): D09960<JP/US>
EFFICACY    Antineoplastic, Janus kinase (JAK) inhibitor
  DISEASE   Myelofibrosis [DS:H01605]
            Polycythemia vera [DS:H00012]
            Acute graft-versus-host disease [DS:H00084]
            Chronic graft-versus-host disease [DS:H00084]
            Atopic dermatitis [DS:H01358]
            Nonsegmental vitiligo [DS:H01372]
TARGET      JAK1 [HSA:3716] [KO:K11217]
            JAK2 [HSA:3717] [KO:K04447]
  PATHWAY   hsa04062(3717)  Chemokine signaling pathway
            hsa04630(3716+3717)  JAK-STAT signaling pathway
            hsa05200(3716+3717)  Pathways in cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2C9 [HSA:1559]
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             D DERMATOLOGICALS
              D11 OTHER DERMATOLOGICAL PREPARATIONS
               D11A OTHER DERMATOLOGICAL PREPARATIONS
                D11AH Agents for dermatitis, excluding corticosteroids
                 D11AH09 Ruxolitinib
                  D09960  Ruxolitinib phosphate (JAN/USAN) &lt;JP/US&gt;
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EJ Janus-associated kinase (JAK) inhibitors
                 L01EJ01 Ruxolitinib
                  D09960  Ruxolitinib phosphate (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Ruxolitinib
                D09960  Ruxolitinib phosphate (JAN/USAN)
             Dermatological Agents
              Dermatitis and Pruitus Agents
               Dermatitis and Pruitus Agents, Other
                Ruxolitinib
                 D09960  Ruxolitinib phosphate (JAN/USAN)
             Immunological Agents
              Immunological Agents, Other
               JAK Inhibitors
                Ruxolitinib
                 D09960  Ruxolitinib phosphate (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D09960  Ruxolitinib phosphate (JAN/USAN)
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09960  Ruxolitinib phosphate (JAN/USAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                DG00719  Ruxolitinib
                 D09960  Ruxolitinib phosphate
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               DG00719  Ruxolitinib
                D09960  Ruxolitinib phosphate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00719  Ruxolitinib
                 D09960  Ruxolitinib phosphate
            Drug classes [BR:br08332]
             Immunological agent
              DG02020  JAK inhibitor
               D09960  Ruxolitinib phosphate
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D09960  Ruxolitinib phosphate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               JAK family
                JAK1
                 D09960  Ruxolitinib phosphate (JAN/USAN) &lt;JP/US&gt;
                JAK2
                 D09960  Ruxolitinib phosphate (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09960
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09960
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09960
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09960
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09960
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                DG00719  Ruxolitinib
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               DG00719  Ruxolitinib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00719  Ruxolitinib
DBLINKS     CAS: 1092939-17-7
            PubChem: 135626685
            ChEBI: 66917
            LigandBox: D09960
ATOM        28
            1   C8x C    28.7700  -22.8200
            2   N5x N    28.7700  -24.2200
            3   C8y C    29.9600  -24.9200
            4   C8y C    31.2200  -24.2200
            5   C8y C    31.2200  -22.8200
            6   N5x N    29.9600  -22.1200
            7   C8x C    32.5500  -24.6400
            8   C8x C    33.3200  -23.5200
            9   N4x N    32.5500  -22.4000
            10  C8y C    29.9600  -26.3200
            11  C8x C    28.8400  -27.1600
            12  N4y N    29.2600  -28.4900
            13  N5x N    30.6600  -28.4900
            14  C8x C    31.1500  -27.1600
            15  C1b C    26.8800  -28.4900
            16  C1c C    28.0700  -29.1900
            17  C1y C    28.0700  -30.5900
            18  C3b C    26.8800  -27.0900
            19  N3a N    26.8800  -25.6900
            20  C1x C    26.9500  -31.4300
            21  C1x C    27.3700  -32.7600
            22  C1x C    28.7700  -32.7600
            23  C1x C    29.1900  -31.4300
            24  O1c O    34.0900  -27.9300
            25  P1b P    35.4900  -27.9300
            26  O1c O    36.8900  -27.9300
            27  O1c O    35.4900  -26.5300
            28  O1c O    35.4900  -29.3300
BOND        30
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    5   9 1
            11    3  10 1
            12   10  11 2
            13   11  12 1
            14   12  13 1
            15   13  14 2
            16   10  14 1
            17   15  16 1
            18   16  12 1
            19   16  17 1 #Up
            20   15  18 1
            21   18  19 3
            22   17  20 1
            23   20  21 1
            24   21  22 1
            25   22  23 1
            26   17  23 1
            27   24  25 1
            28   25  26 1
            29   25  27 2
            30   25  28 1
///
